IOV-4001 for Non-Small Cell Lung Cancer
Study Summary
This trial will test a new cancer treatment called IOV-4001 on people with melanoma or NSCLC that has spread and can't be removed by surgery. They will be measuring how effective and safe it is.
- Non-Small Cell Lung Cancer
- Melanoma
Eligibility Criteria
Inclusion Criteria
You will be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Awards & Highlights
Trial Design
Find a site
Who is running the clinical trial?
Media Library
Frequently Asked Questions
How many individuals are involved in this clinical experiment?
"The sponsor of this trial, Iovance Biotherapeutics Inc., is seeking to enrol a contingent of 53 patients that meet the study's criteria. These individuals will be recruited from locations such as Memorial Sloan Kettering Cancer Center in New York and University of Louisville in Kentucky."
Are there still opportunities for enrolment in this clinical trial?
"Affirmative. Clinicaltrials.gov records support that this clinical trial, which was launched on July 20th 2022, is actively recruiting participants. 53 individuals are needed from 3 locations to complete the study."
What aims is this research endeavor attempting to achieve?
"The primary objective of this study, which will be tracked over a period up to 60 months, is to assess the safety profile of IOV-4001. Secondary endpoints include Disease Control Rate (DCR), Feasibility of IOV-4001 and Overall Survival (OS). Respectively, they measure response rate based on RECIST v1.1 criteria by an investigator, successful manufacturing with no delays or failures, as well as total time from infusion until death due any cause."